Complement Split Products C3a/C5a and Receptors: Are They Regulated by Circulating Angiotensin II Type 1 Receptor Autoantibody in Severe Preeclampsia?

Background: This study measured the serum levels of complement component (C)3a and C5a and the placental expressions of C3a receptor (R) and C5aR to determine a potential correlation with circulating angiotensin II type 1 (AT1) receptor agonistic autoantibody (AT1-AA) in severe pre-eclampsia. Methods: A total of 118 women were recruited and divided into 2 groups: the control group (normotensive pre-term pregnancies, n = 66) and severe pre-eclampsia group (n = 52). Levels of C3a, C5a and All-AA in serum were measured by enzyme-linked immunosorbent assay and C3aR and C5aR in placenta by Western blotting. Results: Levels of C3a, C5a and AT1-AA in serum from the severe pre-eclampsia group were significantly higher than in controls (p <0.05). Placental expression of C3aR and C5aR in the pre-eclampsia group was lower than that in controls (p < 0.05). There were significant positive correlations between levels of C3a, C5a and AT1-AA in serum from the pre-eclampsia group (p < 0.05). In contrast, there was no correlation between C3aR and C5aR in the placenta and AT1-AA in serum in the pre-eclampsia group (p>0.05). Conclusion: Increased C3a, C5a and AT1-AA in the serum provide indirect evidence that AT1-AA mediated activation contributes to activate complement, which is a key mechanism underlying the pathogenesis of severe pre-eclampsia. (C) 2015 S. Karger AG, Basel